Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
February 29, 2016 08:00 ET
|
Assertio Therapeutics, Inc.
NEWARK, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Depomed (NASDAQ:DEPO) today announced that top-line clinical results from a Phase IIb trial of GRT6005 (“cebranopadol’) conducted by Grünenthal...
Depomed Reports Record Fourth Quarter and Full Year 2015 Financial Results
February 22, 2016 16:00 ET
|
Assertio Therapeutics, Inc.
- Record full year 2015 net product sales of $342 million, up 200% year-over-year -- Record fourth quarter net product sales of $111 million, up 228% year-over-year -- NUCYNTA® fourth quarter net...
Depomed to Report Fourth Quarter Fiscal Year 2015 Financial Results on Monday, February 22, 2016
February 16, 2016 08:00 ET
|
Assertio Therapeutics, Inc.
NEWARK, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2015 financial results after the close of market,...
Depomed Announces Favorable Markman Ruling in Nucynta® and Nucynta® ER Patent Litigation
February 08, 2016 08:00 ET
|
Assertio Therapeutics, Inc.
NEWARK, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced today a favorable Markman claim construction ruling by Judge Claire Cecchi of the United States District...
Depomed to Present at Healthcare Conferences in February
February 03, 2016 08:00 ET
|
Assertio Therapeutics, Inc.
NEWARK, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the following healthcare conferences during the month of February. ...
Depomed Announces Save the Date for 2016 Analyst and Investor Day
January 27, 2016 08:00 ET
|
Assertio Therapeutics, Inc.
NEWARK, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will hold an Analyst and Investor Day in New York City on Wednesday, March 23, 2016 from 9:00...
Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From Grunenthal
January 04, 2016 08:00 ET
|
Assertio Therapeutics, Inc.
NEWARK, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that on December 30, 2015 it closed the acquisition of the U.S. and Canadian rights to cebranopadol...